Trials / Recruiting
RecruitingNCT05320198
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Disc Medicine, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Conditions
- Myelofibrosis; Anemia
- Anemia
- Myelofibrosis
- Myelofibrosis Due to and Following Polycythemia Vera
- Primary Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Myelodysplastic Syndromes
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DISC-0974 | DISC-0974 is administered subcutaneously. |
Timeline
- Start date
- 2022-06-06
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2022-04-11
- Last updated
- 2026-03-09
Locations
23 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05320198. Inclusion in this directory is not an endorsement.